Isobolographic analysis of interactions between remacemide and conventional antiepileptic drugs in the mouse model of maximal electroshock

Epilepsy and Behavior

Volumn 11, Issue 1, 2007, Pages 6-12

  Borowicz, Kinga K ^a   Malek, Robert ^a   Luszczki, Jarogniew J ^a   Ratnaraj, Neville ^b   Patsalos, Philip N ^b   Czuczwar, Stanislaw J ^a,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Antiepileptic drugs; Drug interactions; Isobolographic analysis; Maximal electroshock; Pharmacodynamic interaction; Pharmacokinetic interaction; Remacemide

Indexed keywords

1 METHYL 1,2 DIPHENYLETHYLAMINE; CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; REMACEMIDE; VALPROATE MAGNESIUM;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BRAIN LEVEL; DRUG COMPETITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; ELECTRIC SHOCK; LONG TERM MEMORY; LOW DRUG DOSE; MALE; MONOTHERAPY; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PHARMACODYNAMICS; TONIC CLONIC SEIZURE;

ACETAMIDES; ALGORITHMS; ANIMALS; ANTICONVULSANTS; AVOIDANCE LEARNING; BRAIN; CARBAMAZEPINE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ELECTROSHOCK; EPILEPSY; EPILEPSY, TONIC-CLONIC; MALE; MEMORY; MICE; MOTOR SKILLS; PHENOBARBITAL; PHENYTOIN; SEIZURES; VALPROIC ACID;

EID: 34447643554     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2007.04.018     Document Type: Article

References (45)

1. Kwan P., and Brodie M.J. Epilepsy after the first drug fails: substitution or add-on?. Seizure 9 (2000) 464-468
2. Czuczwar S.J., and Borowicz K.K. Polytherapy in epilepsy: the experimental evidence. Epilepsy Res 52 (2002) 15-23
3. Dash A.K., and Elmquist W.F. Separation methods that are capable of revealing blood-brain barrier permeability. J Chromatogr B 797 (2003) 241-254
4. Garske G.E., Palmer G.C., Napier J.J., et al. Preclinical profile of the anticonvulsant remacemide and its enantiomers in the rat. Epilepsy Res 9 (1991) 161-174
5. Palmer G.C., Murray R.J., and Wilson T.C. Biological profile of the metabolites of the anticonvulsant remacemide. Epilepsy Res 12 (1992) 9-20
6. Stagnitto M.L., Palmer G.C., Ordy J.M., et al. Preclinical profile of remacemide: a novel anticonvulsant effective against maximal electroshock seizures in mice. Epilepsy Res 7 (1990) 11-28
7. Palmer G.C., Clark B., and Hutchison J.B. Antiepileptic and neuroprotective potential for remacemide hydrochloride. Drug Future 18 (1993) 1021-1042
8. Cramer C.L., Stagnitto M.L., Knowles M.A., and Palmer G.C. Kainic acid and 4-aminopyridine seizure models in mice: evaluation of efficacy of antiepileptic drugs and calcium antagonists. Life Sci 54 (1994) 1271-1275
9. Meldrum B.S. Update on the mechanism of action of antiepileptic drugs. Epilepsia 37 Suppl. 6 (1996) 4-11
10. Norris S.K., and King A.E. Electrophysiological effects of the anticonvulsant remacemide hydrochloride and its metabolite ARL 12495AA on rat CA1 hippocampal neurons in vitro. Neuropharmacology 36 (1997) 951-959
11. Santangeli S., Sills G.J., Thompson G.G., and Brodie M.J. Na(+) channel effects of remacemide and desglycinyl-remacemide in rat cortical synaptosomes. Eur J Pharmacol 438 (2002) 63-68
12. Wamil A.W., Cheung H., Harris E.W., and McLean M.J. Remacemide HCl and its metabolite, FLP 12495AA, limit potential firing frequency and block NMDA responses of mouse spinal cord neurons in cell culture. Epilepsy Res 23 (1996) 1-14
13. Subramaniam S., Donevan S.D., and Rogawski M.A. Block of the N-methyl-d-aspartate receptor by remacemide and its des-glycine metabolite. J Pharmacol Exp Ther 276 (1996) 161-168
14. Clark B., Hutchison J.B., Jamieson V., Jones T., Palmer G.C., and Scheyer R.D. Potential antiepileptic drugs: remacemide hydrochloride. In: Levy R.H., Mattson R.H., and Meldrum B.S. (Eds). Antiepileptic drugs. 4th ed. (1995), Raven Press, New York 1035-1044
15. Davies J.A. Remacemide hydrochloride: a novel antiepileptic agent. Gen Pharmacol 28 (1997) 499-502
16. Sills G.J., Santangeli S., Forrest G., and Brodie M.J. Influence of cytochrome P450 induction on the pharmacokinetics and pharmacodynamics of remacemide hydrochloride. Epilepsy Res 49 (2002) 247-254
17. Black M.A., Tremblay R., Mealing G.A., Durkin J.P., Whitfield J.F., and Morley P. The desglycinyl metabolite of remacemide hydrochloride is neuroprotective in cultured rat cortical neurons. J Neurochem 66 (1996) 989-995
18. Santangeli S., Sills G.J., Stone T.W., and Brodie M.J. Differential effects of remacemide and desglycinyl-remacemide on epileptiform burst firing in the rat hippocampal slice. Neurosci Lett 321 (2002) 33-36
19. Chadwick D.W., Betts T.A., Broddie H.D., et al. Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg/day) in a Q.I.D. regimen. Seizure 11 (2002) 114-123
20. Jones M.W., Blume W.T., Guberman A., et al. Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 800 mg/day) in a B.I.D. regimen. Seizure 11 (2002) 104-113
21. Devinsky O., Vazquez B., Faught E., et al. A double-blind, placebo-controlled study of remacemide hydrochloride in patients with refractory epilepsy following pre-surgical assessment. Seizure 11 (2002) 371-376
22. Leach J.P., Blacklaw J., Jamieson V., Jones T., Richens A., and Brodie M.J. Mutual interaction between remacemide hydrochloride and carbamazepine: two drugs with active metabolites. Epilepsia 37 (1996) 1100-1106
23. Leach J.P., Grivan J., Jamieson V., Jones T., Richens A., and Brodie M.J. Lack of pharmacokinetic interaction between remacemide hydrochloride and sodium valproate in epileptic patients. Seizure 6 (1997) 179-184
24. Litchfield J.T., and Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96 (1949) 99-113
25. Boissier J.R., Tardy J., and Diverres J.C. Une nouvelle methode simple pour explorer l'action tranquilisante: le test de la cheminee. Med Exp (Basel) 3 (1960) 81-84
26. Venault P., Chapouthier G., De Carvalho L.P., et al. Benzodiazepines impair and beta-carbolines enhance performance in learning and memory tasks. Nature 321 (1986) 864-866
27. Tallarida R.J. Drug synergism and dose-effect data analysis (2000), Chapman & Hall/CRC, Boca Raton, FL
28. Luszczki J.J., Borowicz K.K., Swiader M., and Czuczwar S.J. Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 44 (2003) 489-499
29. 5]enkephalin: a synergistic interaction. Eur J Pharmacol 179 (1990) 463-468
30. Borowicz K.K., Swiader M., Luszczki J., and Czuczwar S.J. Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis. Epilepsia 43 (2002) 956-963
31. Luszczki J.J., and Czuczwar S.J. Isobolographic profile of interaction between tiagabine and gabapentin: a preclinical study. Naunyn Schmiedeberg's Arch Pharmacol 369 (2004) 434-446
32. Löscher W., Fassbender C.P., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. Epilepsy Res 8 (1991) 171-189
33. Garske G.E., Palmer G.C., Napier J.J., et al. Preclinical profile of the anticonvulsant remacemide and its enantiomers in the rat. Epilepsy Res 9 (1991) 161-174
34. Halonen T., Nissinen J., and Pitkanen A. Neuroprotective effect of remacemide hydrochloride in a perforant pathway stimulation model of status epilepticus in the rat. Epilepsy Res 34 (1999) 251-269
35. Stagnitto M.L., Palmer G.C., Ordy J.M., et al. Preclinical profile of remacemide: a novel anticonvulsant effective against maximal electroshock seizures in mice. Epilepsy Res 7 (1990) 11-28
36. Cramer C.L., Stagnitto, Knowles M.A., and Palmer G.C. Kainic acid and 4-aminopyridine seizure models in mice: evaluation of efficacy of anti-epileptic agents and calcium antagonists. Life Sci 54 (1994) PL271-PL275
37. Gasior M., Ungard J.T., and Witkin J.M. Preclinical evaluation of newly approved and potential antiepileptic drugs against cocaine-induced seizures. J Pharmacol Exp Ther 290 (1999) 1148-1156
38. Nehlig A., and Boehrer A. Effects of remacemide in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS. Epilepsy Res 52 (2003) 253-261
39. Richens A., Mawer G., Crawford P., and Harrison B. A placebo-controlled, double-blind cross- over trial of adjunctive one month remacemide hydrochloride treatment in patients with refractory epilepsy. Seizure 9 (2000) 537-543
40. Leach J.P., Marson A.G., and Hutton J.L. Remacemide for drug-resistant localization related epilepsy. Cochrane Database Syst Rev 4 (2002) CD001900
41. Brodie M.J., Wroe S.J., Dean A.D., Holdich T.A., Whitehead J., and Stevens J.W. Efficacy and safety of remacemide versus carbamazepine in newly diagnosed epilepsy: comparison by sequential analysis. Epilepsy Behav 3 (2002) 140-146
42. Deckers C.L., Czuczwar S.J., Hekster Y.A., et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 41 (2000) 1364-1374
43. Deckers C.L., Genton P., Sills G.J., and Schmidt D. Current limitations of antiepileptic drug therapy: a conference review. Epilepsy Res 53 (2003) 1-17
44. Ragsdale D.S., and Avoli M. Sodium channels as molecular targets for antiepileptic drugs. Brain Res Rev 26 (1998) 16-28
45. Czuczwar S.J., and Patsalos P.N. The new generation of GABA enhancers. CNS Drugs 15 (2001) 339-350